These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock. While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight. Given this perspective, it's time to examine the average forecasts of specific CareDx metrics that are routinely monitored and predicted by Wall Street analysts. Analysts predict that the 'Revenue- Patient and digital solutions' will reach $10.04 million. The estimate points to a change of +19.4% from the year-ago quarter. According to the collective judgment of analysts, 'Revenue- Testing services' should come in at $44.07 million. The estimate points to a change of -32.6% from the year-ago quarter.